Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1Breast Neoplasms 1

Interventions

Filgrastim 5Docetaxel 3Carboplatin 3Cyclosporine 2Cyclophosphamide 2sargramostim 1pegfilgrastim 1ixabepilone 1flt3 ligand protein 1eflapegrastim 1Topotecan 1Thrombopoietin 1Taxes 1Stem Cell Factor 1Phenobarbital 1Paclitaxel 1Oxaliplatin 1Mannose-Binding Lectin 1Leucovorin 1Lenalidomide 1Irinotecan 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Etoposide 1Epoetin Alfa 1Epirubicin 1EC regimen 1Doxorubicin 1Diet, High-Fat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neutropenia × EC regimen × Clear all
NCT02527746 2024-02-23

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

EVIVE Biotechnology

Phase 1 Completed
18 enrolled 22 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡